Bottlenecks in the efficient use of advanced therapy medicinal products based on mesenchymal stromal cells

Stem Cells International

Volumn 2015, Issue , 2015, Pages

  Escacena, Natalia ^a   Quesada Hernández, Elena ^b   Capilla Gonzalez, Vivian ^a   Soria, Bernat ^a,c   Hmadcha, Abdelkrim ^a,c  

^a CABIMER Andalusian Center for Molecular Biology and Regenerative Medicine CSIC University of Seville UPO   (Spain)

^b Newbiotechnic SA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; VASCULAR CELL ADHESION MOLECULE 1;

ANTIGEN EXPRESSION; CELL ACTIVATION; CELL DIFFERENTIATION; CELL EXPANSION; CELL FUNCTION; CELL INTERACTION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DISEASE FREE INTERVAL; DISEASE SEVERITY; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; INCIDENCE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MESENCHYMAL STROMA CELL TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SAFETY;

ANIMALIA;

EID: 84939168254     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2015/895714     Document Type: Review

References (115)

1. Y. Jiang, B. N. Jahagirdar, R. L. Reinhardt et al. , "Pluripotency ofmesenchymal stemcells derived from adultmarrow, " Nature, vol. 418, no. 6893, pp. 41-49, 2002.
2. L. da Silva Meirelles, P. C. Chagastelles, and N. B. Nardi, "Mesenchymal stem cells reside in virtually all post-natal organs and tissues, " Journal of Cell Science, vol. 119, no. 11, pp. 2204-2213, 2006.
3. A. I. Caplan, "All MSCs are pericytes?" Cell Stem Cell, vol. 3, no. 3, pp. 229-230, 2008.
4. D. J. Prockop and J. Y. Oh, "Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation, "MolecularTherapy, vol. 20, no. 1, pp. 14-20, 2012.
5. R. J. Petrie, A. D. Doyle, and K. M. Yamada, "Random versus directionally persistent cell migration, " Nature ReviewsMolecular Cell Biology, vol. 10, no. 8, pp. 538-549, 2009.
6. M. J. Hoogduijn, F. Popp, R. Verbeek et al. , "The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy, " International Immunopharmacology, vol. 10, no. 12, pp. 1496-1500, 2010.
7. L. da Silva Meirelles, A. M. Fontes, D. T. Covas, and A. I. Caplan, "Mechanisms involved in the therapeutic properties of mesenchymal stem cells, " Cytokine and Growth Factor Reviews, vol. 20, no. 5-6, pp. 419-427, 2009.
8. C. Shrestha, L. Zhao, K. Chen, H. He, and Z. Mo, "Enhanced healing of diabetic wounds by subcutaneous administration of human umbilical cord derived stem cells and their conditioned media, " International Journal of Endocrinology, vol. 2013, Article ID 592454, 10 pages, 2013.
9. A. Burlacu, G. Grigorescu, A.-M. Rosca, M. B. Preda, and M. Simionescu, "Factors secreted by mesenchymal stem cells and endothelial progenitor cells have complementary effects on angiogenesis in vitro, " Stem Cells and Development, vol. 22, no. 4, pp. 643-653, 2013.
10. A. J. Friedenstein, U. F. Deriglasova, N. N. Kulagina et al. , "Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method, " Experimental Hematology, vol. 2, no. 2, pp. 83-92, 1974.
11. P. A. Zuk, M. Zhu, H. Mizuno et al. , "Multilineage cells from human adipose tissue: implications for cell-based therapies, " Tissue Engineering, vol. 7, no. 2, pp. 211-228, 2001.
12. A. Erices, P. Conget, and J. J. Minguell, "Mesenchymal progenitor cells in human umbilical cord blood, " British Journal of Haematology, vol. 109, no. 1, pp. 235-242, 2000.
13. S. Gronthos, M. Mankani, J. Brahim, P. G. Robey, and S. Shi, "Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo, " Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 25, pp. 13625-13630, 2000.
14. S. Diaz-Prado, E. Muinos-Lopez, T. Hermida-Gomez et al. , "Multilineage differentiation potential of cells isolated from the human amniotic membrane, " Journal of Cellular Biochemistry, vol. 111, no. 4, pp. 846-857, 2010.
15. M. F. Pittenger, "Multilineage potential of adult human mesenchymal stem cells, " Science, vol. 284, no. 5411, pp. 143-147, 1999.
16. M. Owen and A. J. Friedenstein, "Stromal stem cells: marrowderived osteogenic precursors, " Ciba Foundation Symposium, vol. 136, pp. 42-60, 1988.
17. A. I. Caplan, "Mesenchymal stem cells, " Journal of Orthopaedic Research, vol. 9, no. 5, pp. 641-650, 1991.
18. J. E. Dennis, A. Merriam, A. Awadallah, J. U. Yoo, B. Johnstone, and A. I. Caplan, "A quadripotential mesenchymal progenitor cell isolated from the marrow of an adult mouse, " Journal of Bone and Mineral Research, vol. 14, no. 5, pp. 700-709, 1999.
19. P. Bianco and P. G. Robey, "Marrow stromal stem cells, " Journal of Clinical Investigation, vol. 105, no. 12, pp. 1663-1668, 2000.
20. Y. Jiang, B. Vaessen, T. Lenvik, M. Blackstad, M. Reyes, and C. M. Verfaillie, "Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain, " Experimental Hematology, vol. 30, no. 8, pp. 896-904, 2002.
21. M. Dominici, K. Le Blanc, I. Mueller et al. , "Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement, " Cytotherapy, vol. 8, no. 4, pp. 315-317, 2006.
22. A. I. Caplan, "Whats in a name?" Tissue Engineering, Part A, vol. 16, no. 8, pp. 2415-2417, 2010.
23. D. A. de Ugarte, Z. Alfonso, P. A. Zuk et al. , "Differential expression of stem cell mobilization-associated molecules on multi-lineage cells from adipose tissue and bone marrow, " Immunology Letters, vol. 89, no. 2-3, pp. 267-270, 2003.
24. M. Krampera, M. Franchini, G. Pizzolo, and G. Aprili, "Mesenchymal stem cells: from biology to clinical use, " Blood Transfusion, vol. 5, no. 3, pp. 120-129, 2007.
25. Y. Sakaguchi, I. Sekiya, K. Yagishita, and T. Muneta, "Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source, " Arthritis and Rheumatism, vol. 52, no. 8, pp. 2521-2529, 2005.
26. E. Capra, R. Beretta, V. Parazzi et al. , "Changes in the proteomic profile of adipose tissue-derivedmesenchymal stem cells during passages, " Proteome Science, vol. 10, no. 1, article 46, 2012.
27. W. Wagner, S. Bork, G. Lepperdinger et al. , "How to track cellular aging of mesenchymal stromal cells?" Aging, vol. 2, no. 4, pp. 224-230, 2010.
28. K. Tarte, J. Gaillard, J.-J. Lataillade et al. , "Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation, " Blood, vol. 115, no. 8, pp. 1549-1553, 2010.
29. A. I. Caplan, "Why are MSCs therapeutic? New data: new insight, "The Journal of Pathology, vol. 217, no. 2, pp. 318-324, 2009.
30. K. Stenderup, J. Justesen, C. Clausen, and M. Kassem, "Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells, " Bone, vol. 33, no. 6, pp. 919-926, 2003.
31. R. Schäfer, U. Knauf, M. Zweyer et al. , "Age dependence of the human skeletal muscle stem cell in forming muscle tissue, " Artificial Organs, vol. 30, no. 3, pp. 130-140, 2006.
32. D. F. McAuley, G. F. Curley, U. I. Hamid et al. , "Clinical grade allogeneic human mesenchymal stemcells restore alveolar fluid clearance in human lungs rejected for transplantation, " The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 306, no. 9, pp. L809-L815, 2014.
33. J. Liang, H. Zhang, B. Hua et al. , "Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study, " Annals of the Rheumatic Diseases, vol. 69, no. 8, pp. 1423-1429, 2010.
34. D. J. Prockop, "Marrow stromal cells as stem cells for nonhematopoietic tissues, " Science, vol. 276, no. 5309, pp. 71-74, 1997.
35. S. P. Bruder, N. Jaiswal, and S. E. Haynesworth, "Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation, " Journal of Cellular Biochemistry, vol. 64, no. 2, pp. 278-294, 1997.
36. D. Woodbury, K. Reynolds, and I. B. Black, "Adult bonemarrow stromal stem cells express germline, ectodermal, endodermal, and mesodermal genes prior to neurogenesis, " Journal of Neuroscience Research, vol. 69, no. 6, pp. 908-917, 2002.
37. S. Kern, H. Eichler, J. Stoeve, H. Klüter, and K. Bieback, "Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue, " StemCells, vol. 24, no. 5, pp. 1294-1301, 2006.
38. E. M. Horwitz, P. L. Gordon, W. K. K. Koo et al. , "Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone, " Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 13, pp. 8932-8937, 2002.
39. M. D. Nicola, C. Carlo-Stella, M. Magni et al. , "Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli, " Blood, vol. 99, no. 10, pp. 3838-3843, 2002.
40. L. Raffaghello, G. Bianchi, M. Bertolotto et al. , "Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche, " Stem Cells, vol. 26, no. 1, pp. 151-162, 2008.
41. A. Hmadcha, J. Dominguez-Bendala, J. Wakeman, M. Arredouani, and B. Soria, "The immune boundaries for stem cell based therapies: problems and prospective solutions, " Journal of Cellular and Molecular Medicine, vol. 13, no. 8, pp. 1464-1475, 2009.
42. K. Le Blanc, "Immunomodulatory effects of fetal and adult mesenchymal stem cells, " Cytotherapy, vol. 5, no. 6, pp. 485-489, 2003.
43. P. A. Conget and J. J. Minguell, "Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells, " Journal of Cellular Physiology, vol. 181, no. 1, pp. 67-73, 1999.
44. S. Glennie, I. Soeiro, P. J. Dyson, E. W.-F. Lam, and F. Dazzi, "Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells, " Blood, vol. 105, no. 7, pp. 2821-2827, 2005.
45. F. Benvenuto, S. Ferrari, E. Gerdoni et al. , "Human mesenchymal stem cells promote survival of T cells in a quiescent state, " Stem Cells, vol. 25, no. 7, pp. 1753-1760, 2007.
46. J. Stagg, S. Pommey, N. Eliopoulos, and J. Galipeau, "Interferon-γ-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell, " Blood, vol. 107, no. 6, pp. 2570-2577, 2006.
47. A. Uccelli, L. Moretta, and V. Pistoia, "Mesenchymal stem cells in health and disease, " Nature Reviews Immunology, vol. 8, no. 9, pp. 726-736, 2008.
48. C. Menard, L. Pacelli, G. Bassi et al. , "Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls, " Stem Cells and Development, vol. 22, no. 12, pp. 1789-1801, 2013.
49. M. Krampera, L. Cosmi, R. Angeli et al. , "Role for interferon-γ in the immunomodulatory activity of human bone marrow mesenchymal stem cells, " Stem Cells, vol. 24, no. 2, pp. 386-398, 2006.
50. K. N. Sivanathan, S. Gronthos, D. Rojas-Canales, B. Thierry, and P. T. Coates, "Interferon-gamma modification of mesenchymal stem cells: implications of autologous and allogeneicmesenchymal stem cell therapy in allotransplantation, " Stem Cell Reviews and Reports, vol. 10, no. 3, pp. 351-375, 2014.
51. M. Najar, G. Raicevic, H. I. Boufker et al. , "Mesenchymal stromal cells use PGE2 tomodulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Whartons Jelly and bone marrow sources, " Cellular Immunology, vol. 264, no. 2, pp. 171-179, 2010.
52. K. H. Yoo, I. K. Jang, M. W. Lee et al. , "Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues, " Cellular Immunology, vol. 259, no. 2, pp. 150-156, 2009.
53. M. Ricciardi, G. Malpeli, F. Bifari et al. , "Comparison of epithelial differentiation and immune regulatory properties of mesenchymal stromal cells derived from human lung and bone marrow, " PLoS ONE, vol. 7, no. 5, Article ID e35639, 2012.
54. M. Krampera, "Mesenchymal stromal cell licensing: amultistep process, " Leukemia, vol. 25, no. 9, pp. 1408-1414, 2011.
55. H. Wegmeyer, A.-M. BrÖske, M. Leddin et al. , "Mesenchymal stromal cell characteristics vary depending on their origin, " Stem Cells and Development, vol. 22, no. 19, pp. 2606-2618, 2013.
56. J. S. Hunt, M. G. Petroff, R. H. McIntire, and C. Ober, "HLA-G and immune tolerance in pregnancy, " The FASEB Journal, vol. 19, no. 7, pp. 681-693, 2005.
57. J. M. Lee, J. Jung, H.-J. Lee et al. , "Comparison of immunomodulatory effects of placenta mesenchymal stem cells with bone marrow and adipose mesenchymal stem cells, " International Immunopharmacology, vol. 13, no. 2, pp. 219-224, 2012.
58. H. Fazekasova, R. Lechler, K. Langford, and G. Lombardi, "Placenta-derived MSCs are partially immunogenic and less immunomodulatory than bone marrow-derived MSCs, " Journal of Tissue Engineering and Regenerative Medicine, vol. 5, no. 9, pp. 684-694, 2011.
59. S. M. Melief, J. J. Zwaginga, W. E. Fibbe, and H. Roelofs, "Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts, " Stem Cells Translational Medicine, vol. 2, no. 6, pp. 455-463, 2013.
60. A. Bartholomew, C. Sturgeon, M. Siatskas et al. , "Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo, " Experimental Hematology, vol. 30, no. 1, pp. 42-48, 2002.
61. G. Ren, J. Su, L. Zhang et al. , "Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression, " Stem Cells, vol. 27, no. 8, pp. 1954-1962, 2009.
62. M. Krampera, J. Galipeau, Y. Shi, K. Tarte, and L. Sensebe, "Immunological characterization of multipotent mesenchymal stromal cells-the international society for cellular therapy (ISCT) working proposal, " Cytotherapy, vol. 15, no. 9, pp. 1054-1061, 2013.
63. E. Zappia, S. Casazza, E. Pedemonte et al. , "Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy, " Blood, vol. 106, no. 5, pp. 1755-1761, 2005.
64. D. Gordon, G. Pavlovska, C. P. Glover, J. B. Uney, D. Wraith, and N. J. Scolding, "Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration, " Neuroscience Letters, vol. 448, no. 1, pp. 71-73, 2008.
65. M. Rafei, E. Birman, K. Forner, and J. Galipeau, "Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis, " MolecularTherapy, vol. 17, no. 10, pp. 1799-1803, 2009.
66. G. Constantin, S. Marconi, B. Rossi et al. , "Adipose-derivedmesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis, " Stem Cells, vol. 27, no. 10, pp. 2624-2635, 2009.
67. L. Bai, D. P. Lennon, V. Eaton et al. , "Human bone marrowderivedmesenchymal stem cells induceTh2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis, " Glia, vol. 57, no. 11, pp. 1192-1203, 2009.
68. J. Zhang, Y. Li, J. Chen et al. , "Human bonemarrow stromal cell treatment improves neurological functional recovery in EAE mice, " Experimental Neurology, vol. 195, no. 1, pp. 16-26, 2005.
69. L. Sun, D. Wang, J. Liang et al. , "Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus, " Arthritis and Rheumatism, vol. 62, no. 8, pp. 2467-2475, 2010.
70. M. A. Gonzalez, E. Gonzalez-Rey, L. Rico, D. Büscher, and M. Delgado, "Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells, " Arthritis and Rheumatism, vol. 60, no. 4, pp. 1006-1019, 2009.
71. M. Jurewicz, S. Yang, A. Augello et al. , "Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes, " Diabetes, vol. 59, no. 12, pp. 3139-3147, 2010.
72. P. Fiorina, M. Jurewicz, A. Augello et al. , "Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes, " The Journal of Immunology, vol. 183, no. 2, pp. 993-1004, 2009.
73. R. H. Lee, M. J. Seo, R. L. Reger et al. , "Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 46, pp. 17438-17443, 2006.
74. M. Sudres, F. Norol, A. Trenado et al. , "Bonemarrowmesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice, " The Journal of Immunology, vol. 176, no. 12, pp. 7761-7767, 2006.
75. V. Tisato, K. Naresh, J. Girdlestone, C. Navarrete, and F. Dazzi, "Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease, " Leukemia, vol. 21, no. 9, pp. 1992-1999, 2007.
76. R. Yanez, M. L. Lamana, J. Garcia-Castro, I. Colmenero, M. Ramirez, and J. A. Bueren, "Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease, " Stem Cells, vol. 24, no. 11, pp. 2582-2591, 2006.
77. H. M. Lazarus, O. N. Koc, S. M. Devine et al. , "Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients, " Biology of Blood and Marrow Transplantation, vol. 11, no. 5, pp. 389-398, 2005.
78. O. N. Koc, S. L. Gerson, B. W. Cooper et al. , "Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy, " Journal of Clinical Oncology, vol. 18, no. 2, pp. 307-316, 2000.
79. K. Le Blanc, I. Rasmusson, B. Sundberg et al. , "Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells, " The Lancet, vol. 363, no. 9419, pp. 1439-1441, 2004.
80. O. Ringden, M. Uzunel, I. Rasmusson et al. , "Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease, " Transplantation, vol. 81, no. 10, pp. 1390-1397, 2006.
81. B. Fang, Y. P. Song, L. M. Liao, Q. Han, and R. C. Zhao, "Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells, " BoneMarrow Transplantation, vol. 38, no. 5, pp. 389-390, 2006.
82. H. Ning, F. Yang, M. Jiang et al. , "The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study, " Leukemia, vol. 22, no. 3, pp. 593-599, 2008.
83. M. Krampera, S. Sartoris, F. Liotta et al. , "Immune regulation by mesenchymal stem cells derived fromadult spleen and thymus, " Stem Cells and Development, vol. 16, no. 5, pp. 797-810, 2007.
84. F. Djouad, P. Plence, C. Bony et al. , "Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals, " Blood, vol. 102, no. 10, pp. 3837-3844, 2003.
85. M. Galie, G. Konstantinidou, D. Peroni et al. , "Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice, " Oncogene, vol. 27, no. 18, pp. 2542-2551, 2008.
86. B. Mazzanti, A. Aldinucci, T. Biagioli et al. , "Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: implication for assessment of disease activity and treatment, " Journal of Neuroimmunology, vol. 199, no. 1-2, pp. 142-150, 2008.
87. Z. G. Zhao, Y. Liang, K. Li et al. , "Phenotypic and functional comparison of mesenchymal stem cells derived from the bone marrow of normal adults and patients with hematologic malignant diseases, " Stem Cells and Development, vol. 16, no. 4, pp. 637-648, 2007.
88. B. Li, J. Fu, P. Chen, and W. Zhuang, "Impairment in immunomodulatory function of mesenchymal stem cells from multiple myeloma patients, " Archives of Medical Research, vol. 41, no. 8, pp. 623-633, 2010.
89. Y.-H. Chao, C.-T. Peng, H.-J. Harn, C.-K. Chan, and K.-H. Wu, "Poor potential of proliferation and differentiation in bone marrow mesenchymal stem cells derived from children with severe aplastic anemia, " Annals of Hematology, vol. 89, no. 7, pp. 715-723, 2010.
90. A. Bacigalupo, M. Valle, M. Podesta et al. , "T-cell suppression mediated by mesenchymal stemcells is deficient in patients with severe aplastic anemia, " Experimental Hematology, vol. 33, no. 7, pp. 819-827, 2005.
91. H. A. Papadaki, H. D. Kritikos, C. Gemetzi et al. , "Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha-mediated effect, " Blood, vol. 99, no. 5, pp. 1610-1619, 2002.
92. M.-C. Kastrinaki, P. Sidiropoulos, S. Roche et al. , "Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis, " Annals of the Rheumatic Diseases, vol. 67, no. 6, pp. 741-749, 2008.
93. J. A. Perez-Simon, S. Tabera, M. E. Sarasquete et al. , "Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura, " Cytotherapy, vol. 11, no. 6, pp. 698-705, 2009.
94. Y. Nie, C. Lau, A. Lie, G. Chan, and M. Mok, "Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus, " Lupus, vol. 19, no. 7, pp. 850-859, 2010.
95. L. Y. Sun, H. Y. Zhang, X. B. Feng, Y. Y. Hou, L. W. Lu, and L. M. Fan, "Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus, " Lupus, vol. 16, no. 2, pp. 121-128, 2007.
96. P. Cipriani, S. Guiducci, I. Miniati et al. , "Impairment of endothelial cell differentiation frombonemarrow-derivedmesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis, " Arthritis and Rheumatism, vol. 56, no. 6, pp. 1994-2004, 2007.
97. L. Shin and D. A. Peterson, "Impaired therapeutic capacity of autologous stem cells in a model of type 2 diabetes, " Stem Cells Translational Medicine, vol. 1, no. 2, pp. 125-135, 2012.
98. S. Kume, S. Kato, S.-I. Yamagishi et al. , "Advanced glycation endproducts attenuate humanmesenchymal stemcells and prevent cognate differentiation into adipose tissue, cartilage, and bone, " Journal of Bone and Mineral Research, vol. 20, no. 9, pp. 1647-1658, 2005.
99. C. Cramer, E. Freisinger, R. K. Jones et al. , "Persistent high glucose concentrations alter the regenerative potential of mesenchymal stem cells, " Stem Cells and Development, vol. 19, no. 12, pp. 1875-1884, 2010.
100. L. Acosta, A. Hmadcha, N. Escacena et al. , "Adipose mesenchymal stromal cells isolated from type 2 diabetic patients display reduced fibrinolytic activity, " Diabetes, vol. 62, no. 12, pp. 4266-4269, 2013.
101. B. Wang, S.-M. Wu, T. Wang et al. , "Pre-treatment with bonemarrow-derived mesenchymal stemcells inhibits systemic intravascular coagulation and attenuates organ dysfunction in lipopolysaccharide-induced disseminated intravascular coagulation rat model, " Chinese Medical Journal, vol. 125, no. 10, pp. 1753-1759, 2012.
102. G. Moll, I. Rasmusson-Duprez, L. vonBahr et al. , "Are therapeutic human mesenchymal stromal cells compatible with human blood?" Stem Cells, vol. 30, no. 7, pp. 1565-1574, 2012.
103. S. Benvenuti, I. Cellai, P. Luciani et al. , "Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells, " Journal of Endocrinological Investigation, vol. 30, no. 9, pp. RC26-RC30, 2007.
104. S. Lee, J.-R. Park, M.-S. Seo et al. , "Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells, " Cell Proliferation, vol. 42, no. 6, pp. 711-720, 2009.
105. G. Moll, A. Hult, L. von Bahr et al. , "Do ABOblood group antigens hamper the therapeutic efficacy of mesenchymal stromal cells?" PLoS ONE, vol. 9, no. 1, Article ID e85040, 2014.
106. C. A. Herberts, M. S. G. Kwa, and H. P. H. Hermsen, "Risk factors in the development of stem cell therapy, " Journal of Translational Medicine, vol. 9, article 29, 2011.
107. M. Breitbach, T. Bostani, W. Roell et al. , "Potential risks of bone marrow cell transplantation into infarcted hearts, " Blood, vol. 110, no. 4, pp. 1362-1369, 2007.
108. U. Kunter, S. Rong, P. Boor et al. , "Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes, " Journal of the American Society of Nephrology, vol. 18, no. 6, pp. 1754-1764, 2007.
109. Y. Wang, D. I. Huso, J. Harrington et al. , "Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture, " Cytotherapy, vol. 7, no. 6, pp. 509-519, 2005.
110. G. V. Røsland, A. Svendsen, A. Torsvik et al. , "Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation, " Cancer Research, vol. 69, no. 13, pp. 5331-5339, 2009.
111. L. Sensebe, M. Gadelorge, and S. Fleury-Cappellesso, "Production of mesenchymal stromal/stem cells according to good manufacturing practices: a review, " Stem Cell Research and Therapy, vol. 4, no. 3, article 66, 2013.
112. P. Galvez, B. Clares, M. Bermejo, A. Hmadcha, and B. Soria, "Standard requirement of a microbiological quality control programfor themanufacture of humanmesenchymal stem cells for clinical use, " Stem Cells and Development, vol. 23, no. 10, pp. 1074-1083, 2014.
113. D. G. Phinney, "Functional heterogeneity of mesenchymal stem cells: implications for cell therapy, " Journal of Cellular Biochemistry, vol. 113, no. 9, pp. 2806-2812, 2012.
114. D. G. Phinney, G. Kopen, W. Righter, S. Webster, N. Tremain, and D. J. Prockop, "Donor variation in the growth properties and osteogenic potential of human marrow stromal cells, " Journal of Cellular Biochemistry, vol. 75, no. 3, pp. 424-436, 1999.
115. J. Ancans, "Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development, " Frontiers in Immunology, vol. 3, article 253, 2012.